Clinical Trials Logo

Central Retinal Vein Occlusion clinical trials

View clinical trials related to Central Retinal Vein Occlusion.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04667910 Not yet recruiting - Clinical trials for Central Retinal Vein Occlusion

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Start date: December 2020
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO

NCT ID: NCT02522897 Not yet recruiting - Clinical trials for Central Retinal Vein Occlusion With Macular Edema

Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas

PEARL
Start date: August 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if additional panretinal photocoagulation of ischemic areas following retinal vein occlusion (RVO) may reduce the rate of recurrence and allow longer treatment intervals in anti-Vascular Endothelial Growth Factor (VEGF) treatment following the "trea-and-extend" scheme.

NCT ID: NCT01303276 Not yet recruiting - Clinical trials for Central Retinal Vein Occlusion

Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)

Start date: June 2011
Phase: N/A
Study type: Observational

Ranibizumab (Lucentis, Genentech) is an off-label drug used for the clinical treatment of central retinal vein occlusion, which is one of the most common retinal vascular disorders. Despite its clinical effectiveness, concerns remain regarding the systemic effects of the drug and previous studies have noted retinal arteriolar vasoconstriction following a ranibizumab injection. We aim to provide a physiological basis to these observations by assessing retinal blood flow before and after the ranibizumab injections. Specifically, we will assess the blood flow parameters (i.e. retinal vessel diameter, velocity & flow) immediately before the first injection and post-injection over a follow-up continued treatment period.

NCT ID: NCT00383773 Not yet recruiting - Clinical trials for Central Retinal Vein Occlusion

Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion

Start date: October 2006
Phase: N/A
Study type: Interventional

Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about 71 micron will enter a branch retinal vein and TPA will be injected into the obstracted vein.